Infliximab Reverses Symptoms and May Protect from Developing Chronic Restrictive Ophthalmopathy in Children with Familial Orbital Myositis: A Case Report

Ocul Immunol Inflamm. 2023 Jul;31(5):1097-1100. doi: 10.1080/09273948.2022.2074464. Epub 2022 May 27.

Abstract

Background: Orbital myositis is a rare sporadic eye disease associated with extraocular eye muscle inflammation. To date, there have been two reports of familial orbital myositis (FOM), which demonstrate partially penetrant autosomal dominant inheritance.

Cases: We report six new Australian cases of FOM, four of whom extend one of the reported pedigrees, as well as a separate mother and daughter manifesting orbital myositis, which constitutes a third report of familial occurrence. We can confirm that the disease has onset in childhood, appearing to go into remission in adult life, and that the inflammation is corticosteroid-responsive. However, one patient went on to develop permanent diplopia in upgaze. We also report two children suffering chronic pain and diplopia who demonstrated complete resolution of symptoms with the anti-TNF-α monoclonal infliximab.

Conclusion: Uncontrolled FOM in childhood may result in permanent extraocular eye muscle damage, while TNF-α blockade provides an excellent steroid-sparing effect.

Keywords: Autosomal dominant; children; familial; infliximab; orbital myositis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Australia
  • Child
  • Diplopia / complications
  • Humans
  • Inflammation / complications
  • Infliximab / therapeutic use
  • Orbital Diseases* / diagnosis
  • Orbital Myositis* / diagnosis
  • Orbital Myositis* / drug therapy
  • Orbital Myositis* / etiology
  • Tumor Necrosis Factor Inhibitors

Substances

  • Infliximab
  • Tumor Necrosis Factor Inhibitors